The initial guideline regarding the prime prevention of cervical cancer has been released by the American Society of Clinical Oncology or ASCO. The guideline takes into account the different situations around the globe.
In a press release, Silvina Arrossi, PhD, a researcher at Instituto Nacional del Cancer in Buenos Aires, Argentina, and one of the panelists who collaborated the guidelines, said, “Although HPV vaccine has been around for more than a decade, the uptake of the vaccine has been less than ideal in many places, including in high-resource countries such as the United States. As an organization of cancer doctors, the ASCO continues to endorse HPV vaccination programs and efforts to help spare more women around the world from this very difficult cancer.”
You can find the guideline in the Journal of Global Oncology. They used the four levels of resource settings such as basic, limited, enhanced and maximal as the basis of their recommendations.
In the guideline, girls who are 9 to 14 years old can have two doses of HPV vaccine and this is carried on in all four levels of resource settings. They can receive the doses in minimum of 6 months up to a maximum of 12 to 15 months intervals. Three doses of the HPV vaccine are recommended if the girl is HIV-positive.
In the maximal and enhanced level of resource settings, girls who are 15 years old and above can complete the series provided the first dosage was administered before they reached the age of 15. If this is not the case, three doses of the HPV vaccine are recommended. This guideline is applicable in both cases until the girls are 26 years old.
For the basic and limited resource settings, the girls who are 9-14 years old and had been administered their first dosage can receive another dosage when they are 15 years old until they 26 years of age.
Boys are not recommended to get vaccination under the basic settings. However, under the maximal, enhanced and limited settings, can receive the HPV vaccine for the prevention of other non-cervical HPV–related cancers and diseases.
A Result of a Comprehensive Study
ASCO releases global guidance on HPV vaccination for cervical cancer prevention as a result of a comprehensive study of the collected works on the subject from 1966 to 2015. According to Silvina Arrossi, and her entire team of researchers, this global guideline works very well with the other global, resource-stratified guidelines on cervical cancer by the American Society of Clinical Oncology or ASCO. There are also specific elements of the HPV guidelines established by WHO, CDC, and guideline-issuing authorities in Australia, Canada and Germany that are highlighted by the said guideline.
Another panelist from those who developed the guideline, Silvia de Sanjosé, MD, PhD, head of the cancer epidemiology research program at Institut Català d’Oncologia in Barcelona, Spain said in a press release, “Because resource availability varies widely, both among and within countries, we need to adjust strategies to improve access to HPV vaccination everywhere.”
“This guideline is unique in offering cervical cancer vaccination recommendations that can be adapted to different resource levels, and we expect it to have a major impact on the global health community,” she added.